29 April 2020
Visiongain has launched a new pharma report Active Pharmaceutical Ingredient Market Report 2020-2030: Forecasts by Synthesis (Biotech, Synthetic), by Manufacturer (Captive APIs, Merchant APIs), by API Type (Generic APIs, Innovative APIs), by Application (Cardiology, Oncology, CNS & Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global Active Pharmaceutical Ingredient market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to surpass USD xyz billion by 2020. The growth rate is attributed to growing biopharmaceutical sectors and rising geriatric population across the globe.
To access the data contained in this document please email email@example.com
Active pharmaceutical ingredients comprise all active portions of any drug. Thus, the reactions and results differ depending on the dosage administered by the drug. Good quality APIs are essential for producing effective and safe medicinal products. Manufacturers use certain standards to determine the potency of API in each medication.
The role of API manufacturers is evolving owing to rising pressures from competitors coupled with changing customer demands. Also, branded drug companies as compared to generic manufacturers are increasingly looking beyond their usual group of closely-knit European suppliers. Meanwhile, traditional generic companies are looking towards Asian economies for bulk active pharmaceutical ingredients. To remain competitive in the global active pharmaceutical ingredient market, the market players need to stick to evolving market trends.
Innovators have historically relied on a small number of suppliers they work with in confidence. Innovators often opt to perform the final stages of API synthesis themselves, outsourcing (at most) late-stage intermediate production. While this pattern continues to predominate, innovators have started looking beyond their current European suppliers to realize benefits from partnerships with manufacturers of Indian and Chinese APIs.
North America holds the majority of market share owing to the rising incidence of chronic diseases, growing government focus of generic drugs, rising demands for biologics & specialty drugs. Furthermore, North America depends on China and India for APIs, the COVID-19 pandemic across the Asia Pacific region has resulted in shortages due to amendments in import and export policies across the region. This is anticipated to restrain market growth over the course on the next 2 years.
Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to low drug penetration, rising disposable income coupled with growing healthcare expenditure in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the Active Pharmaceutical Ingredient market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Active Pharmaceutical Ingredient market.
The comprehensive market report features companies such as Abbvie Inc., Astrazeneca, Aurobindo Pharma, Albemarle Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, Glaxosmithkline Plc, Merck & Co., Inc., Mylan N.V., Cipla Inc., Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Ltd., Dr. Reddy’s Laboratories Ltd. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The biologics market is estimated at US$447 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034.
20 November 2023
The global mRNA Vaccines market is estimated at US$11,773.3 million in 2023 and is projected to grow at a CAGR of 10.5% during the forecast period 2023-2033.
08 November 2023
The global Stem Cell Technologies and Applications market is estimated at US$10,059.6 million in 2023 and is projected to grow at a CAGR of 8.7% during the forecast period 2023-2033.
06 November 2023
The global Neurology Clinical Trials market is valued at US$9,609.2 million in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period 2023-2033.